The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
Open accessAbstract
Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti‐inflammatory, anticonvulsant, anti‐oxidant, anti‐emetic, anxiolytic and antipsychotic agent, and is therefore a potential medicine for the treatment of neuroinflammation, epilepsy, oxidative injury, vomiting and nausea, anxiety and schizophrenia, respectively. The neuroprotective potential of CBD, based on the combination of its anti‐inflammatory and anti‐oxidant properties, is of particular interest and is presently under intense preclinical research in numerous neurodegenerative disorders. In fact, CBD combined with Δ 9‐tetrahydrocannabinol is already under clinical evaluation in patients with Huntington's disease to determine its potential as a disease‐modifying therapy. The neuroprotective properties of CBD do not appear to be exerted by the activation of key targets within the endocannabinoid system for plant‐derived cannabinoids like Δ 9‐tetrahydrocannabinol, i.e. CB 1 and CB 2 receptors, as CBD has negligible activity at these cannabinoid receptors, although certain activity at the CB 2 receptor has been documented in specific pathological conditions (i.e. damage of immature brain). Within the endocannabinoid system, CBD has been shown to have an inhibitory effect on the inactivation of endocannabinoids (i.e. inhibition of FAAH enzyme), thereby enhancing the action of these endogenous molecules on cannabinoid receptors, which is also noted in certain pathological conditions. CBD acts not only through the endocannabinoid system, but also causes direct or indirect activation of metabotropic receptors for serotonin or adenosine, and can target nuclear receptors of the PPAR family and also ion channels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Self-citationPertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Self-citationBisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Self-citationCannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · cited 1×
“Moreover, CBD has recently shown an interesting profile for psychiatric disorders, for example, it may serve as an antipsychotic then becoming a promising compound for the treatment of schizophrenia [14-17], but it has also potential as anxiolytic [18] and antidepressant [19], then being also effective for other psych…”
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
Self-citationThomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Self-citationNonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 568
Self-citationLigresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., & Di Marzo, V. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105247 · Cited by 568
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · cited 2×
“However, contrarily to ∆ 9 tetrahydrocannabinol (∆ 9 -THC), the major psychoactive plant-derived cannabinoid, which combines therapeutic properties with some important adverse effects, CBD is not psychoactive (it does not activate CB1 receptors [2]), it is well-tolerated and exhibits a broad spectrum of therapeutic pr…”
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 508
Self-citationCarrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410 · cited 5×
“However, it has been recently proposed that CBD may bind the nuclear receptors of the PPAR family, in particular the PPAR-g [38] [39] (Table 1) and it is well known that these receptors antagonize the action of NFkB, reducing the expression of pro-inflammatory enzymes (i.e. iNOS, COX-2), proinflammatory cytokines and…”
InfluentialLastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Self-citationCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402
Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N., Cuadrado, A., & de Ceballos, M. L. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071290 · Cited by 398
Self-citationMicroglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382
Self-citationAntidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1Areceptors
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., & Guzmán, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.001 · Cited by 362
Self-citationIuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361
García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320
Self-citationControlled clinical trial of cannabidiol in Huntington's disease
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., & Schram, K. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 320
Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., & Behl, C. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00716.x · Cited by 315
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · cited 4×
“merit investigation in parkinsonian patients (reviewed in [9,99]), as previous data obtained in clinical studies have indicated that CBD was effective in the relief of some PD-related symptoms such as dystonia, although not in others like tremor [100], but its combination with ∆(9)-THC, which can activate CB1 receptor…”
InfluentialEsposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308
Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305 · cited 1×
“memory-impairing effects and anxiety produced by ∆(9)-THC [108].”
Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study
Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000140288.48796.8e · Cited by 286
Resstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283
Castillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279
Regulation of nausea and vomiting by cannabinoids
Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01176.x · Cited by 268
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255
Self-citationEsposito, G., De Filippis, D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0025-1 · Cited by 252
O'Sullivan, S. E., & Kendall, D. A. (2010) · Immunobiology · doi:10.1016/j.imbio.2009.09.007 · Cited by 247
Costa, B., Colleoni, M., Conti, S., Parolaro, D., Franke, C., Trovato, A. E., & Giagnoni, G. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-004-0871-3 · Cited by 242
El-Remessy, A. B., Khalil, I. E., Matragoon, S., Abou-Mohamed, G., Tsai, N.-J., Roon, P., Caldwell, R. B., Caldwell, R. W., Green, K., & Liou, G. I. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63558-4 · Cited by 235
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
Schubart, C. D., Sommer, I. E. C., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S., & Boks, M. P. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.017 · Cited by 226
Mishima, K., Hayakawa, K., Abe, K., Ikeda, T., Egashira, N., Iwasaki, K., & Fujiwara, M. (2005) · Stroke · doi:10.1161/01.str.0000163083.59201.34 · Cited by 226
Esposito, G., De Filippis, D., Maiuri, M. C., De Stefano, D., Carnuccio, R., & Iuvone, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.047 · Cited by 225
Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.02.017 · Cited by 223
Cannabidiol: A Promising Drug for Neurodegenerative Disorders?
Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., & Steardo, L. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00065.x · Cited by 215
The endocannabinoid system as a target for the treatment of motor dysfunction
Fernández‐Ruiz, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00088.x · Cited by 214
Self-citationGarcía, C., Palomo‐Garo, C., García‐Arencibia, M., Ramos, J., Pertwee, R., & Fernández‐Ruiz, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01278.x · Cited by 211
Self-citationMukhopadhyay, P., Rajesh, M., Horváth, B., Bátkai, S., Park, O., Tanchian, G., Gao, R. Y., Patel, V., Wink, D. A., Liaudet, L., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.02.021 · Cited by 205
Self-citationNeuroprotective Antioxidants from Marijuanaa
HAMPSON, A. J., GRIMALDI, M., LOLIC, M., WINK, D., ROSENTHAL, R., & AXELROD, J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06193.x · Cited by 203
Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres‐Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., et al. (2009) · Glia · doi:10.1002/glia.20838 · Cited by 201
Self-citationLoss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease
Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M. R., Resel, E., Palazuelos, J., Julien, B., Salazar, M., Börner, C., et al. (2011) · Brain · doi:10.1093/brain/awq278 · Cited by 201
Self-citationInhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol
Ross, H. R., Napier, I., & Connor, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707104200 · Cited by 199
Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., & Parolaro, D. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6156-x · Cited by 196
Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & DeVane, C. L. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098541 · Cited by 192
Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben‐Nun, A., Juknat, A., & Vogel, Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01379.x · Cited by 190
Biochemistry of postmortem brains in Parkinson’s disease: historical overview and future prospects
Nagatsu, T., & Sawada, M. (2007) · Neuropsychiatric Disorders An Integrative Approach · doi:10.1007/978-3-211-73574-9_14 · Cited by 184
Maione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., de Novellis, V., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01063.x · Cited by 175
Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2036-z · Cited by 174
Yamaori, S., Kushihara, M., Yamamoto, I., & Watanabe, K. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.028 · Cited by 165 · cited 1×
“PPAR-γ) [38,39], and many other pharmacological targets (see Table 1 including refs [40-56]).”
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041384 · Cited by 164
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 157
Ahrens, J., Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., Karst, M., & Haeseler, G. (2009) · Pharmacology · doi:10.1159/000201556 · Cited by 154
Alvarez, F. J., Lafuente, H., Rey-Santano, M. C., Mielgo, V., Gastiasoro, E., Rueda, M. A., Pertwee, R. G., Castillo, A. I., Romero, J., & Martínez-Orgado, J. A. (2008) · Pediatric Research · doi:10.1203/pdr.0b013e318186e5dd · Cited by 153
Self-citationEffect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew)
Parker, L. A., Kwiatkowska, M., Burton, P., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1571-2 · Cited by 152
Self-citationOpen label evaluation of cannabidiol in dystonic movement disorders
Consroe, P. F., Sandyk, R., & Snider, S. R. (1986) · International Journal of Neuroscience · doi:10.3109/00207458608985678 · Cited by 150
Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147
Self-citationCannabidiol arrests onset of autoimmune diabetes in NOD mice
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.029 · Cited by 147
Self-citationMagen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00589.x · Cited by 143
Self-citationProspects for cannabinoid therapies in basal ganglia disorders
Fernández‐Ruíz, J., Moreno‐Martet, M., Rodríguez‐Cueto, C., Palomo‐Garo, C., Gómez‐Cañas, M., Valdeolivas, S., Guaza, C., Romero, J., Guzmán, M., Mechoulam, R., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01365.x · Cited by 136
Self-citationRuiz‐Valdepeñas, L., Martínez-Orgado, J. A., Benito, C., Millán‐Uclés, Á., Tolón, R. M., & Romero, J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-5 · Cited by 135
Self-citationKwiatkowska, M., Parker, L., Burton, P., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1739-9 · Cited by 135
Self-citationSumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., Mechoulam, R., & Feldmann, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20050 · Cited by 134
Self-citationDurst, R. Y., Danenberg, H. D., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., & Lotan, C. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00098.2007 · Cited by 134
Self-citationCannabidiol, a constituent of Cannabis sativa, modulates sleep in rats
Murillo‐Rodríguez, E., Millán‐Aldaco, D., Palomero‐Rivero, M., Mechoulam, R., & Drucker-Colín, R. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.102 · Cited by 125
Self-citationTherapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease
Ohno, Y. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00211.x · Cited by 115
Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112
Rock, E. M., Goodwin, J. M., Limebeer, C. L., Breuer, A., Pertwee, R. G., Mechoulam, R., & Parker, L. A. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2157-4 · Cited by 111
Self-citationSastre‐Garriga, J., Vila, C., Clissold, S. P., & Montalbán, X. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.47 · Cited by 108
Yang, K. S., Galadari, S., Isaev, D. S., Petroianu, G. A., Shippenberg, T. S., & Öz, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162594 · Cited by 108
Valdeolivas, S., Satta, V., Pertwee, R. G., Fernández‐Ruíz, J., & Sagredo, O. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200114w · Cited by 107
Self-citationJuknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Coppola, G., Geschwind, D. H., & Vogel, Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01461.x · Cited by 106
Sagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., & Fernández‐Ruiz, J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22682 · Cited by 105
Self-citationThe endocannabinoid system as a target for the treatment of neuronal damage
Fernández‐Ruíz, J., García, C., Sagredo, O., Gómez‐Ruíz, M., & de Lago, E. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003709792 · Cited by 105
Self-citationAvraham, Y., Grigoriadis, N. K., Poutahidis, T., Vorobiev, L., Magen, I., Ilan, Y., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01179.x · Cited by 103
Self-citationLafuente, H., Alvarez, F. J., Pazos, M. R., Alvarez, A. A., Rey-Santano, M. C., Mielgo, V., Murgia-Esteve, X., Hilario, E., & Martínez-Orgado, J. A. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e3182276b11 · Cited by 97
Self-citationHayakawa, K., Mishima, K., Nozako, M., Ogata, A., Hazekawa, M., Liu, A.-X., Fujioka, M., Abe, K., Hasebe, N., Egashira, N., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.005 · Cited by 89
Dupre, K. B., Jaunarajs, K. L. E., Barnum, C. J., & Bishop, C. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.031 · Cited by 85
Filippis, D. D., Iuvone, T., D’Amico, A., Esposito, G., Steardo, L., Herman, A. G., Pelckmans, P. A., Winter, B. Y. D., & Man, J. G. D. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01114.x · Cited by 80
Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent.
Sreevalsan, S., Joseph, S., Jutooru, I., Chadalapaka, G., & Safe, S. H. (2011) · PubMed · Cited by 79
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
Hayakawa, K., Mishima, K., & Fujiwara, M. (2010) · Pharmaceuticals · doi:10.3390/ph3072197 · Cited by 78
Braida, D., Pegorini, S., Arcidiacono, M. V., Consalez, G. G., Croci, L., & Sala, M. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00569-x · Cited by 73
Lastres‐Becker, I., Bizat, N., Boyer, F., Hantraye, P., Brouillet, E., & Fernández‐Ruíz, J. (2003) · Neuroreport · doi:10.1097/00001756-200305060-00007 · Cited by 69
Jenny, M., Santer, E., Pirich, E., Schennach, H., & Fuchs, D. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.12.004 · Cited by 62
Huntington's disease: progress toward effective disease-modifying treatments and a cure
Johnson, C. D., & Davidson, B. L. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq148 · Cited by 59
Roze, E. F., Bonnet, C., Bétuing, S., & Caboche, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_5 · Cited by 59
Marijuana extracts possess the effects like the endocrine disrupting chemicals
Watanabe, K., Motoya, E., Matsuzawa, N., Funahashi, T., Kimura, T., Matsunaga, T., Arizono, K., & Yamamoto, I. (2004) · Toxicology · doi:10.1016/j.tox.2004.08.005 · Cited by 54
The Seek of Neuroprotection: Introducing Cannabinoids
Martínez-Orgado, J. A., Fernández‐López, D., Lizasoaín, I., & Romero, J. (2007) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488907780832724 · Cited by 51
Self-citationDifferential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids
Yamaori, S., Maeda, C., Yamamoto, I., & Watanabe, K. (2011) · Forensic Toxicology · doi:10.1007/s11419-011-0112-7 · Cited by 49
Takeda, S., Usami, N., Yamamoto, I., & Watanabe, K. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026930 · Cited by 46
Koch, M., Dehghani, F., Habazettl, I., Schomerus, C., & Korf, H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03873.x · Cited by 28
Cannabidiol in dystonic movement disorders
Sandyk, R., Snider, S. R., Consroe, P. F., & Elias, S. M. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90117-4 · Cited by 27
Cannabidiol-treated Rats Exhibited Higher Motor Score After Cryogenic Spinal Cord Injury
Kwiatkoski, M., Guimarães, F. S., & Bel, E. A. D. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9273-8 · Cited by 26
Funahashi, T., Ikeuchi, H., Yamaori, S., Kimura, T., Yamamoto, I., & Watanabe, K. (2005) · Eisei kagaku · doi:10.1248/jhs.51.369 · Cited by 7
Cited by
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Crini, G., Lichtfouse, E., Chanet, G., & Morin-Crini, N. (2020) · Environmental Chemistry Letters · doi:10.1007/s10311-020-01029-2 · Cited by 396
Metadata
- Authors
- Fernández‐Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez‐Orgado, J.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-01-10
- Volume
- 75
- Issue
- 2
- Pages
- 323-333
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2113535405
- Cited by
- 349
- References
- 105
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.